Literature DB >> 21029018

A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells.

Inna V Larsen1, Curtis R Brandt.   

Abstract

UNLABELLED: Abstract Purpose: To determine if a peptide, TAT-Cd(0), inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells.
METHODS: TAT-Cd(0) and a control peptide, E(50,51)TAT-Cd(0), were added at various times throughout infection with the lacz-expressing hrR3 virus, and viral replication was measured by β-galactosidase activity. Toxicity was assessed using a dye reduction assay.
RESULTS: The CC(50) value for TAT-Cd(0) was ∼100 μM. In assays with peptide present at all times, TAT-Cd(0) was 150-fold more active than E(50,51)TAT-Cd(0) (EC(50) 0.2 vs. 30.0 μM). The EC(50) values of TAT-Cd(0) for entry inhibition, cell protection, virus inactivation, and inhibition of attachment were 0.1, 0.4, 9.5, and 3.0 μM, respectively. TAT-Cd(0) was less effective when added 1 h postinfection (EC(50) = 30.0 μM).
CONCLUSIONS: TAT-Cd(0) is an effective inhibitor of Herpes simplex virus type 1 infection in human corneal epithelial cells and affects multiple steps before, or very early, in infection. The peptide has potential as an antiviral and further studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21029018      PMCID: PMC2990285          DOI: 10.1089/jop.2010.0076

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  22 in total

1.  Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans.

Authors:  M Tyagi; M Rusnati; M Presta; M Giacca
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

2.  Peptides containing membrane-transiting motifs inhibit virus entry.

Authors:  Hermann Bultmann; Curtis R Brandt
Journal:  J Biol Chem       Date:  2002-07-18       Impact factor: 5.157

3.  Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain.

Authors:  Hermann Bultmann; Jeremy Teuton; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

4.  Corneal toxicity of cell-penetrating peptides that inhibit Herpes simplex virus entry.

Authors:  Radeekorn Akkarawongsa; Amy E Cullinan; Andrew Zinkel; Joshua Clarin; Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2006-08       Impact factor: 2.671

Review 5.  Herpes simplex virus epidemiology and ocular importance.

Authors:  T J Liesegang
Journal:  Cornea       Date:  2001-01       Impact factor: 2.651

6.  Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells.

Authors:  Jeremy C Jones; Elizabeth A Turpin; Hermann Bultmann; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

7.  Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide.

Authors:  S E Altmann; J C Jones; S Schultz-Cherry; C R Brandt
Journal:  Virology       Date:  2009-04-22       Impact factor: 3.616

8.  Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group.

Authors: 
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

9.  Evaluation of a theta-defensin in a Murine model of herpes simplex virus type 1 keratitis.

Authors:  Curtis R Brandt; Radeekorn Akkarawongsa; Sharon Altmann; Gilbert Jose; Aaron W Kolb; Alan J Waring; Robert I Lehrer
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-11       Impact factor: 4.799

10.  Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.

Authors:  Radeekorn Akkarawongsa; Nina E Pocaro; Gary Case; Aaron W Kolb; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

View more
  3 in total

Review 1.  Peptide therapeutics for treating ocular surface infections.

Authors:  Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2014-09-24       Impact factor: 2.671

2.  A cationic peptide, TAT-Cd°, inhibits herpes simplex virus type 1 ocular infection in vivo.

Authors:  Gilbert G Jose; Inna V Larsen; Joshua Gauger; Erica Carballo; Rebecca Stern; Rachel Brummel; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-05       Impact factor: 4.799

Review 3.  Genital Herpes: Insights into Sexually Transmitted Infectious Disease.

Authors:  Dinesh Jaishankar; Deepak Shukla
Journal:  Microb Cell       Date:  2016-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.